News & Events

< Back to News Overview

Neurovance Appoints Jeff Bailey to Chair Its Board of Directors

07 / 01 / 2016

Mr. Bailey Brings 30 Years of Expertise to Neurovance and to Its Development of Centanafadine for Adult ADHD

Cambridge, MA January 7, 2016 Neurovance, Inc. today announced the appointment of Jeff Bailey as Executive Chairman of the Company’s Board of Directors.  He brings nearly 30 years of experience from a wide range of earlier leadership positions. Mr. Bailey had previously been President and Chief Executive Officer of Lantheus Medical Imaging Inc. until August,  2015. Earlier, he served as Chief Operating Officer of Fougera Pharmaceuticals and Chief Commercial Officer for King Pharmaceuticals.  He also held executive positions at Novartis Pharmaceuticals and Johnson and Johnson (and at the J&J subsidiary, Janssen Pharmaceuticals).  Mr. Bailey earned a business degree from Rutgers University in New Jersey.

 Jeff brings broad business experience as we advance our lead product candidate  centanafadine through later-stage clinical trials,” said Anthony A. McKinney, President and CEO of Neurovance. “His broad leadership experience from management to commercialization to sales will be important as we accelerate our development program.”

Centanafadine (CTN) is a triple reuptake inhibitor, with effects on norepinephrine, dopamine and serotonin aimed at treating attention deficit hyperactivity disorder (ADHD). Previous studies   have demonstrated that CTN has efficacy that may be comparable to stimulants currently used  to treat ADHD. In addition, centanafadine may have lower risk of abuse liability than stimulants. According to a recent report, adult ADHD is among the most rapidly growing diagnoses affecting Americans, with nearly 5 million privately insured individuals treated medically for ADHD as of 2012.

Mr. Bailey commented, Centanafadine offers a unique approach to treating ADHD with a targeted mechanism of action. I am pleased to chair the Company’s Board while this novel treatment moves toward a phase 2b/3a clinical trial, expected later this year.

Mr. Bailey will join current board members Campbell Murray, M.D. from Novartis Venture Funds (formerly the Chair of the Neurovance board), Paul Weiss, Ph.D. from Venture Investors, Daniel

R. Omstead, Ph.D. from Tekla Capital Management, Brigitte Smith, M.B.A. from GBS Venture Partners, Timothy Barberich, and Anthony McKinney, Neurovance President and CEO.  Mr. Bailey will also Chair the board of directors of Euthymics Bioscience, a sibling company developing a triple reuptake inhibitor with a different ratio than CTN’s, optimized to treat addictive disorders.




Anthony A. McKinney, 617-758-0300       


Media: Initiate PR 

Stephen Gendel, 424-371-9600